Gromit Therapeutics develops gene therapies targeting inflammatory and age-related diseases in both human and animal health. The company’s pipeline includes programs for cardiovascular and pulmonary conditions in humans, as well as orthopedic, spinal, and cardiovascular disorders in companion animals. An ongoing veterinary clinical study has enrolled over thirty patients, providing initial evidence of safety and efficacy outcomes, with a follow-up period exceeding one year. These findings aim to support veterinary drug development and inform investigational new drug applications for human indications. It employs a dual go-to-market and research and development strategy to facilitate clinical development. The company has also filed a trademark application for “KHEPRI,” intended to cover testing, inspection, research, or development of pharmaceutical preparations for gene therapy.
